Latest SATVI news:
++++++++++++++++++++
Article in ‘International Innovation’ April 2016: Determining a prognostic risk signature for clinical tuberculosis.
++++++++++++++++++++
24 March 2016: LANCET ARTICLE: A test to predict the risk of developing TB disease
A landmark study is to be published this month in the leading medical journal, The Lancet, reporting the discovery of a blood test that can predict whether someone is likely to develop tuberculosis (TB) disease, long before the disease manifests.
On the eve of World TB day (24 March) a landmark study has been published this month in the leading medical journal, The Lancet, reporting the discovery of a blood test that can predict whether someone is likely to develop tuberculosis (TB) disease, long before the disease manifests.
This is a game changer in the fight against TB because this prognostic blood test, which is based on the human immune response, can predict whether a person will develop tuberculosis more than 12 months in advance.
“Targeting only those individuals who are truly at risk of tuberculosis disease for preventive antibiotic therapy is something that we desperately need in our battle against this devastating epidemic,” according to Dr Thomas Scriba, Associate Professor at the University of Cape Town.
Read the whole story on the SATVI website.
++++++++++++++++++++
2 March 2016: SATVI releases its Annual Report 2015.
++++++++++++++++++++
17 November 2015: SATVI announces its participation in 46th Union World Conference on Lung Health in Cape Town from 2-6 December 2015
The South African Tuberculosis Vaccine Initiative has announced its participation in the 46th Union World Conference on Lung Health, which will be taking place in Cape Town from 2-6 December 2015. Everyone is invited to visit the SATVI field site and/or laboratory. Read more on the SATVI website.
+++++++++++++++++++++
SATVI is a tuberculosis research group accommodating several disciplines including paediatrics, infectious diseases, epidemiology, public health, immunology and clinical/biological sciences. SATVI has large and well-developed clinical field site in the Boland Overberg region, with the core on the premises of the Brewelskloof TB Hospital in Worcester, from where most clinical/epidemiological studies and clinical trials of new TB vaccines are conducted.
The Immunology and Laboratory based work is led by Associate Professor Tom Scriba; and the Clinical Trials work is led by SATVI Director, Associate Professor Mark Hatherill.
SATVI Director, Associate Professor: Mark Hatherill
Deputy Director, Head Immunology and Laboratories Associate Professor: Tom Scriba
Field Site Manager: Mrs Marwou de Kock
Communications Manager: Kelvin Vollenhoven
Our Clinical Research Team:
Investigators:
Dr Angelique Luabeya
Dr Justin Shenje
Dr Michele Tameris
Dr Hennie Geldenhuys
Research Officers
Dr Adam Penn-Nicholson
Dr Elisa Nemes
NEWS:
9 October 2015 SATVI commences with Phase 2a TB vaccine candidate.
New MTBVAC TB Study announced.
27 August VPM TB Vaccine study in new-born infants commences.
25 June 2015 First participant in Impaact P1113 study vaccinated.
13 April 2015 New diagnostic approach for early detection of Tuberculosis.